Sponsor content
245 result(s) found, displaying 1 to 10
- ARTGRYBREVANT amivantamab 350 mg/7 mL concentrate for solution for infusion vial (376832)Australian Register of Therapeutic Goods (ARTG) information for RYBREVANT amivantamab 350 mg/7 mL concentrate for solution for infusion vial.
- Australian Public Assessment Report (AusPAR)AusPAR: PonvoryFor the treatment of adult patients with relapsing forms of multiple sclerosis
- Australian Public Assessment Report (AusPAR)AusPAR: Dazalex SCAusPAR for DARZALEX SC (daratumumab) for the treatment of light chain AL amyloidosis
- May-2022Prescription medicine evaluationIMBRUVICA Janssen-Cilag Pty LtdActive ingredient: ibrutinib.
- Prescription medicine decision summaryPonvoryTGA decision: Ponvory (ponesimod) is approved to treat relapsing forms of multiple sclerosis.
- ARTGPONVORY ponesimod 2 mg + 3 mg + 4 mg + 5 mg + 6 mg + 7 mg + 8 mg + 9 mg + 10 mg film-coated tablets (Treatment initiation pack) blister composite pack (370320)Australian Register of Therapeutic Goods (ARTG) information for PONVORY ponesimod 2 mg + 3 mg + 4 mg + 5 mg + 6 mg + 7 mg + 8 mg + 9 mg + 10 mg film-coated tablets (Treatment initiation pack) blister composite pack.
- ARTGPONVORY ponesimod 20 mg film-coated tablet blister pack (370319)Australian Register of Therapeutic Goods (ARTG) information for PONVORY ponesimod 20 mg film-coated tablet blister pack.
- Designation or determinationNotice for teclistamab (Janssen-Cilag Pty Ltd)Provisional determination